CDK4 and breast cancer: Interestingly, previous studies have reported that breast cancer patients carrying p53 mutations are more likely to respond poorly to CDK4/6i (Patnaik et al, 2016), and that breast cancer cells with wild‐type p53 are more sensitive to radiotherapy (Fernández‐Aroca et al, 2019).